8月25日晚间，国产隐形正畸企业时代天使（06699.HK）发布2025年上半年业绩报告显示，报告期内实 现收入1.61亿美元，较去年同期上涨33.1%；实现净利润0.14亿美元（存款利息收入及理财产品收益共 8.8百万美元），同比上涨583.6%。根据Wind数据，这也是近三年来，时代天使首次在中期业绩中录得 净利润正增长。 从核心业务表现看，贡献近53.4%营收的隐形矫治解决方案，实现收入0.86亿美元，隐形矫治总案例数 同比增长47.7%达到约22.58万例。其中，中国市场案例数约10.86万例，同比增长14%；国际市场案例数 约11.72万例，同比增长103.5%。国际市场案例数的翻倍增长，也意味着时代天使在全球市场布局中的 持续突破。 不过"出海"扩张之路并非坦途。8月18日，全球隐形矫治领域巨头爱齐科技宣布对时代天使提起专利侵 权诉讼。诉讼指控时代天使的产品及相关软件侵犯了爱齐的多项专利，涵盖多层矫治器材料、尖端治疗 方案设计和先进矫治器功能等创新成果。爱齐科技方面明确表示，这些法律行动已在美国、欧洲和中国 启动，"这些地区是爱齐在创新、矫治器制造和治疗方案设计方面投入巨资的司法管辖区。" 对此， ...

Core Viewpoint - The company has disclosed that it is currently undergoing a review by the USPTO regarding the validity of a patent held by its subsidiary, which has been challenged by a related company, CSPC Baike. The outcome of this review may have implications for the company's intellectual property rights and ongoing drug development efforts [1][2]. Group 1 - The review initiated by CSPC Baike questions the validity of a patent held by the company's subsidiary, which is currently under examination by the USPTO [1][2]. - The compound in question, Compound 1, is identical to CSPC Baike's Compound 10, but the company's patent application was submitted over three months earlier than CSPC's [1]. - The company has expressed confidence in the validity of its patent and is prepared to take necessary legal actions to defend its intellectual property rights if the review proceeds [2]. Group 2 - The patent in question is based on proprietary technology developed by the company and is currently being utilized in the research and development of its candidate drug ASC30 [2]. - The USPTO granted the patent to the company's subsidiary on February 25, 2025, based on its novelty and non-obviousness compared to existing technologies [2]. - The company asserts that the ongoing review does not currently impact its business operations or overall group performance [2].

Core Viewpoint - The announcement highlights a patent review initiated by Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, questioning the validity of a patent held by Gilead Sciences (China) Co., Ltd. [1][2] Group 1: Patent Review and Legal Context - CSPC's Conjupro Biotherapeutics has filed a review with the USPTO challenging the validity of Gilead's U.S. patent (Patent No. 12,234,236) claims 1-9, 12-17, and 21-25 [1] - The compound structure of CSPC's pending application (Compound 10) is identical to Gilead's patented Compound 1, which was granted by the USPTO on February 25, 2025 [2] - Gilead's management received a global licensing request from CSPC regarding the GLP-1R agonist Compound 1 in late March 2025, which Gilead declined [2] Group 2: Company Confidence and Current Operations - The company expresses confidence in the validity of its patent and is prepared to take necessary legal actions to defend its intellectual property if the review proceeds [3] - Currently, the review does not pose any potential impact on the group's operations, and the company will closely monitor the situation [3]

Core Viewpoint - The draft revision of the Shandong Provincial Patent Regulations aims to enhance the protection of patent rights, adapt to new developments in intellectual property, and promote the transformation and application of patents in the region [3][4]. Group 1: Legislative Background - The original Shandong Provincial Patent Regulations were implemented in 2013, and the need for revision arises from changes in national patent laws and the evolving landscape of intellectual property [3]. - The revision is necessary to align with the latest legislative spirit regarding the protection of patent rights and the promotion of patent implementation and conversion [3][4]. Group 2: Key Changes in the Draft - The draft consists of 6 chapters and 53 articles, reducing the original structure from seven chapters to six, with significant updates to the content [5]. - New legislative goals include fostering new quality productivity and promoting high-quality economic and social development through comprehensive patent protection [5][6]. - The draft emphasizes the creation and protection of patents in new technologies, industries, and business models, including the promotion of artificial intelligence applications [5][6]. Group 3: Administrative Penalties - The draft introduces administrative penalties for three types of violations: aiding infringement, repeated infringement, and non-compliance with exhibition infringement rulings, with fines ranging from 5,000 to 100,000 yuan [7][8]. - Specific penalties include fines for providing support to infringing activities and for failing to comply with corrective measures during exhibitions [7][8]. Group 4: Overseas Patent Risk Management - The draft outlines the establishment of an overseas patent risk prevention system, addressing high costs and insufficient talent in dealing with international disputes [9]. - It emphasizes the government's role in supporting enterprises in overseas patent layout and enhancing their ability to respond to overseas patent disputes [9].